Mirae Asset Global Investments Co. Ltd. Reduces Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Mirae Asset Global Investments Co. Ltd. lessened its position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 56.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 114,011 shares of the company’s stock after selling 145,918 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.12% of Poseida Therapeutics worth $383,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Silverarc Capital Management LLC increased its holdings in Poseida Therapeutics by 21.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock valued at $8,492,000 after purchasing an additional 622,037 shares during the period. Strs Ohio purchased a new position in Poseida Therapeutics during the 3rd quarter valued at about $47,000. Barclays PLC increased its holdings in Poseida Therapeutics by 40.7% during the 3rd quarter. Barclays PLC now owns 45,542 shares of the company’s stock valued at $109,000 after purchasing an additional 13,174 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Poseida Therapeutics by 186.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,857 shares of the company’s stock valued at $816,000 after purchasing an additional 223,280 shares during the period. Finally, Keystone Financial Group purchased a new position in Poseida Therapeutics during the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Stock Performance

Poseida Therapeutics stock opened at $2.13 on Friday. The stock’s 50 day simple moving average is $3.03 and its two-hundred day simple moving average is $2.93. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.18 and a current ratio of 3.18. The stock has a market cap of $205.52 million, a price-to-earnings ratio of -1.53 and a beta of 0.36. Poseida Therapeutics, Inc. has a fifty-two week low of $1.54 and a fifty-two week high of $4.27.

Poseida Therapeutics (NASDAQ:PSTX) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.09. The business had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $12.50 million. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. As a group, analysts expect that Poseida Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a report on Monday, April 22nd.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.